Investigation Overview
July 28, 2015 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Thoratec Corporation (NASDAQ:THOR), was announced concerning whether the takeover of Thoratec Corporation by St. Jude Medical for $63.50 per share is unfair to NASDAQ:THOR stockholders.
The investigation by a law firm concerns whether certain officers and directors of Thoratec Corporation breached their fiduciary duties owed to NASDAQ:THOR investors in connection with the proposed acquisition.
On July 22, 2015, St. Jude Medical (NYSE:STJ) and Thoratec Corporation (NASDAQ:THOR) announced that the Boards of Directors of both companies have unanimously approved an agreement under which St. Jude Medical will acquire all of the outstanding shares of Thoratec for $63.50 per share in a cash transaction valued at approximately $3.4 billion, net of cash acquired.
However, the investigation concerns whether the offer is unfair to NASDAQ:THOR stockholders. More specifically, the investigation concerns whether the Thoratec Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.